Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion type Assertion NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_head.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion description "[The validated primary endpoint assay, a peptide-specific CD8+ IFNgamma ELISPOT, was tested in a pre-trial study and found to be suitable for the detection of low frequency naturally occurring CEA- and prostate-derived tumour-antigen-specific T cells in patients with CEA-expressing malignancies and prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_provenance.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion evidence source_evidence_literature NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_provenance.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion SIO_000772 19066888 NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_provenance.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion wasDerivedFrom befree-20140225 NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_provenance.
- NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_assertion wasGeneratedBy ECO_0000203 NP866417.RAAWGmf4WtADxMnHqP1mv_6XyAm97-_t1oeq8L6w5O6bo130_provenance.